ANTHONY VALLARINO: Open Payments
NPI 1497963698 · MELISSA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$881 in 45 payments from 20 companies in 2025. Trend: 2023 $573 · 2024 $671 · 2025 $881
Food & beverage: $881
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $113 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $89 |
| GlaxoSmithKline, LLC. | 4 | $85 |
| Dexcom, Inc. | 4 | $77 |
| Abbott Laboratories | 3 | $74 |
| PFIZER INC. | 3 | $70 |
| Lilly USA, LLC | 3 | $52 |
| Amgen Inc. | 3 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| Antares Pharma, Inc. | 2 | $35 |
Products named: Kerendia, Dexcom G6 Transmitter, PREVNAR 20, Ozempic, MOUNJARO, TRELEGY ELLIPTA, BREZTRI, FREESTYLE LIBRE 3.
Industry payments across TX — which companies pay providers there.
